Sun Pharma reports bigger-than-expected rise in Q2 profit

The company's generic version of popular cancer drug Revlimid is also a significant contributor to the total sales.

Published On 2023-11-01 07:00 GMT   |   Update On 2023-11-01 13:49 GMT
Advertisement

Hyderabad: Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a bigger-than-expected rise in second-quarter profit on Wednesday, driven by strong sales in its domestic and U.S. formulation businesses.

Consolidated net profit after tax rose to 23.76 billion rupees ($285.37 million) for the quarter ended Sept. 30, from 22.62 billion rupees a year earlier.

Analysts, on average, had expected net profit of 23.04 billion rupees, according to LSEG data.

Advertisement

Sales from its U.S. formulation business rose 7.9% to 35.5 billion rupees during the quarter, while sales from its India formulations rose 11.1% to 38.43 billion rupees.

Both businesses account for 30% and 32% of total sales, respectively, Sun Pharma said.

The company's generic version of popular cancer drug Revlimid is also a significant contributor to the total sales.

Mumbai-based Sun Pharma, one of India's oldest drugmakers, which also makes popular consumer healthcare products like Revital vitamin pills and pain relief gel Volini, said its total revenue from operations rose 11.3% to 121.92 billion rupees.

The company, founded in 1983, makes generics and specialty medications for chronic and acute treatments, over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients.

Rivals Dr Reddy's and Cipla last week reported better-than-expected profit on strong U.S. demand.

Read also: Sun Pharma to now offer Desidustat, first oral treatment for CKD-associated anaemia in India under brand Rytstat

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News